Nyrada Inc - Annual Report 2021

Annual Report FY21 55 14. Subsidiaries 2021 ownership interest 2020 ownership interest Nyrada Pty Ltd 1 100% 100% Norbio No.2 Pty Ltd 100% 100% Cardio Therapeutics Pty Ltd 100% 100% 1 On 13 March 2020 the Company changed its name from Norbio No1 Pty Ltd to Nyrada Pty Ltd. 15. Events after reporting period On 30 July 2021 the Company announced it had been granted a US Patent for its PCSK9 Inhibitor. On 13 August 2021 the Company announced exploratory analysis results from its in vivo cholesterol efficacy study. No other matters or circumstances have arisen since 30 June 2021 that have significantly affected, or may significantly affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial years. 16. Cash flow information Reconciliation of loss after income tax to net cash used in operating activities Reconciliation of loss after income tax to net cash used in operating activities 2021 2020 $ $ Loss after income tax expense for the year (3,539,253) (5,773,667) Adjustments for: - - Depreciation & amortisation 1,811 1,484 Share-based payments 1,111,622 2,204,324 Unwinding of the interest on convertible notes - 140,355 Change in operating assets and liabilities Decrease/(increase) in trade and other receivables (281,976) (1,078,839) Increase/(decrease) in trade and other payables (98,620) 95,028 Increase/(decrease) in employee benefits 33,568 692 (2,772,848) (4,410,623) Reconciliation of Cash Cash at the end of financial year as included in the statement of cash flows is reconciled to the related items in the statement of financial position as follows: 2021 2020 $ $ Cheque account 220,229 100,056 USD account 4,122,025 298,724 Saving bonus 9,408,489 4,747,389 13,750,743 5,146,169